| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
1 Division of Hematology, Department of Internal Medicine, Growth and Development Research Institute, University Hospital Maastricht, the Netherlands and 2 Division of Developmental Immunology, Tumor Immunology Program, German Cancer Research Center, Heidelberg, Germany
Requests for reprints: W.T.V. Germeraad, Division of Hematology, Department of Internal Medicine, University Hospital Maastricht, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Phone: 31-433884300; E-mail: w.germeraad{at}immuno.unimaas.nl.
Expression of tissue-restricted self-antigens in the thymus, termed promiscuous gene expression, imposes T cell tolerance and protects from autoimmune diseases. This antigen pool also includes various types of tumor-associated antigens (TAA) previously thought to be secluded from the immune system. The scope of promiscuous gene expression has been defined by mRNA analysis at the global level of isolated medullary thymic epithelial cells (mTECs). Information at the protein level on the frequency of mTECs expressing a given antigen, on coexpression patterns, and post-translational modifications is largely missing. We report here promiscuous expression at the protein level of two TAA, MUC1 and CEA, in situ and in purified human mTECs. Both antigens are expressed in 1% to 3% of mTECs, either individually or coexpressed in the same cell. Using a panel of anti-MUC1 monoclonal antibodies recognizing different post-translational modifications, i.e., glycoforms of MUC1, we show that only fully glycosylated forms of MUC1 and the differentiation-dependent glycoforms were detected on mTECs, but not the cancer-associated glycoforms. Our findings imply that MUC1 and CEA are amenable to central tolerance induction, which might, however, be incomplete in case of tumor cellrestricted MUC1 glycoforms. Knowledge of these subtleties in promiscuous gene expression may, in the future, assist the selection of T cell tumor vaccines for clinical trials. [Cancer Res 2007;67(8):391926]
This article has been cited by other articles:
![]() |
M. R. Parkhurst, J. Joo, J. P. Riley, Z. Yu, Y. Li, P. F. Robbins, and S. A. Rosenberg Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells Clin. Cancer Res., January 1, 2009; 15(1): 169 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tassi, F. Gavazzi, L. Albarello, V. Senyukov, R. Longhi, P. Dellabona, C. Doglioni, M. Braga, V. Di Carlo, and M. P. Protti Carcinoembryonic Antigen-Specific but Not Antiviral CD4+ T Cell Immunity Is Impaired in Pancreatic Carcinoma Patients J. Immunol., November 1, 2008; 181(9): 6595 - 6603. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kondo, B. Maecker, M. R. Weihrauch, C. Wickenhauser, W. Zeng, L. M. Nadler, J. L. Schultze, and M. S. von Bergwelt-Baildon Cyclin D1-Specific Cytotoxic T Lymphocytes Are Present in the Repertoire of Cancer Patients: Implications for Cancer Immunotherapy Clin. Cancer Res., October 15, 2008; 14(20): 6574 - 6579. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Derbinski, S. Pinto, S. Rosch, K. Hexel, and B. Kyewski Promiscuous gene expression patterns in single medullary thymic epithelial cells argue for a stochastic mechanism PNAS, January 15, 2008; 105(2): 657 - 662. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |